Target Name: SLC30A9
NCBI ID: G10463
Review Report on SLC30A9 Target / Biomarker Content of Review Report on SLC30A9 Target / Biomarker
SLC30A9
Other Name(s): GAC63 | C4orf1 | HuEL | Solute carrier family 30 member 9 | znT-9 | Human embryonic lung protein | ZNT9 | Zinc transporter 9 | GRIP1-dependent nuclear receptor coactivator | human embryonic lung protein | Expressed in human embryonic lung | ZnT-9 | HUEL | solute carrier family 30 (zinc transporter), member 9 | expressed in human embryonic lung | ZNT9_HUMAN | BILAPES | solute carrier family 30 member 9

SLC30A9: A protein involved in GABA transport and cellular processes

SLC30A9 (GAC63) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to be involved in a number of cellular processes. Several studies have suggested that SLC30A9 may be a drug target or biomarker, and research is ongoing to determine its potential role in human disease.

SLC30A9 is a member of the SLC (solute carrier family) 30, which is a family of proteins that transport a variety of molecules across cell membranes. These proteins are involved in a wide range of physiological processes, including the transport of nutrients, hormones, and other signaling molecules. SLC30A9 is thought to be involved in the transport of a molecule called GABA (??-amino-??-carboxylic acid), which is a neurotransmitter that plays a role in a number of cellular processes, including anxiety, depression, and fatigue.

SLC30A9 has been shown to be involved in the regulation of GABA transport in the brain. Studies have shown that SLC30A9 is expressed in the brain and that it is involved in the uptake and transport of GABA. Additionally, SLC30A9 has been shown to play a role in modulating the levels of GABA in the brain, which may have implications for the treatment of neurological disorders.

In addition to its role in GABA transport, SLC30A9 is also thought to be involved in the regulation of other cellular processes. For example, studies have shown that SLC30A9 is involved in the transport of amino acids, which are important for the growth and maintenance of brain cells. Additionally, SLC30A9 has been shown to be involved in the regulation of inflammation, which is a critical process for the development and progression of many diseases.

SLC30A9 is also of interest as a potential biomarker for certain diseases. The regulation of GABA transport is thought to be involved in the treatment of a number of neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Additionally, the regulation of GABA transport may also be involved in the treatment of other disorders, such as anxiety and depression.

In conclusion, SLC30A9 (GAC63) is a protein that is involved in a number of cellular processes, including the regulation of GABA transport in the brain. Its function is not well understood, but it is thought to be involved in the regulation of GABA transport and other cellular processes. Further research is needed to fully understand the role of SLC30A9 in human disease.

Protein Name: Solute Carrier Family 30 Member 9

Functions: Mitochondrial proton-coupled zinc ion antiporter mediating the export of zinc from the mitochondria and involved in zinc homeostasis, zinc mobilization as well as mitochondrial morphology and health (PubMed:28334855, PubMed:34397090, PubMed:35614220, PubMed:34433664). In nucleus, functions as a secondary coactivator for nuclear receptors by cooperating with p160 coactivators subtypes. Plays a role in transcriptional activation of Wnt-responsive genes (By similarity)

The "SLC30A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC30A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SLC31A1 | SLC31A2 | SLC32A1 | SLC33A1 | SLC34A1 | SLC34A2 | SLC34A3 | SLC35A1 | SLC35A2 | SLC35A3 | SLC35A4 | SLC35A5 | SLC35B1 | SLC35B2 | SLC35B3 | SLC35B4 | SLC35C1 | SLC35C2 | SLC35D1 | SLC35D2 | SLC35D3 | SLC35E1 | SLC35E1P1 | SLC35E2A | SLC35E2B | SLC35E3 | SLC35E4 | SLC35F1 | SLC35F2 | SLC35F3 | SLC35F4 | SLC35F5 | SLC35F6 | SLC35G1 | SLC35G2 | SLC35G3 | SLC35G4 | SLC35G5 | SLC35G6 | SLC36A1 | SLC36A2 | SLC36A3 | SLC36A4 | SLC37A1 | SLC37A2 | SLC37A3 | SLC37A4 | SLC38A1 | SLC38A10 | SLC38A11 | SLC38A2 | SLC38A3 | SLC38A4 | SLC38A4-AS1 | SLC38A5 | SLC38A6 | SLC38A7 | SLC38A8 | SLC38A9 | SLC39A1 | SLC39A10 | SLC39A11 | SLC39A12 | SLC39A13 | SLC39A14 | SLC39A2 | SLC39A3 | SLC39A4 | SLC39A5 | SLC39A6 | SLC39A7 | SLC39A8 | SLC39A9 | SLC3A1 | SLC3A2 | SLC40A1 | SLC41A1 | SLC41A2 | SLC41A3 | SLC43A1 | SLC43A2 | SLC43A3 | SLC44A1 | SLC44A2 | SLC44A3 | SLC44A3-AS1 | SLC44A4 | SLC44A5 | SLC45A1 | SLC45A2 | SLC45A3 | SLC45A4 | SLC46A1 | SLC46A2 | SLC46A3 | SLC47A1 | SLC47A1P2 | SLC47A2 | SLC48A1 | SLC49A3